JEB -- Anctil et al. 208 (10): 2005 Figure IG6

(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.

Fig. 6. Recordings of effects of the soluble guanylate cyclase inhibitor ODQ (1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one) and of cGMP-specific phosphodiesterase inhibitor zaprinast on peristaltic contractions of reduced preparations. Note the enhancing effect of ODQ in contrast to the additive depressing effects of zaprinast and db cGMP. The latter two also depressed basal tension below initial level (dotted line).